Spruce Street Capital LP Acquires Shares of 1,088,731 Enanta Pharmaceuticals, Inc. $ENTA

Key Points

• Spruce Street Capital LP acquired 1,088,731 Enanta Pharmaceuticals shares during the second quarter, representing approximately 3.74% of the company and 3.1% of the fund’s portfolio.
• Institutional investors own approximately 94.99% of Enanta’s outstanding stock, while the shares recently traded at $14.10, within a 52-week range of $7.05 to $17.15.
• Enanta reported a quarterly loss of $0.67 per share and revenue of $14.36 million, missing analyst expectations; despite the weak results, analysts’ consensus rating remains “Moderate Buy” with an average price target of $19.50.

Spruce Street Capital LP bought a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,088,731 shares of the biotechnology company's stock, valued at approximately $15,873,698,000. Enanta Pharmaceuticals makes up 3.1% of Spruce Street Capital LP's investment portfolio, making the stock its 11th largest position. Spruce Street Capital LP owned approximately 3.74% of Enanta Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Meeder Asset Management Inc. acquired a new position in Enanta Pharmaceuticals during the 4th quarter worth $32,000. Seven Fleet Capital Management LP bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth $36,000. Strs Ohio acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enanta Pharmaceuticals by 333.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 2,758 shares during the last quarter. Finally, Clearstead Trust LLC acquired a new stake in Enanta Pharmaceuticals in the second quarter worth about $74,000. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $14.10 on Tuesday. The stock has a 50 day simple moving average of $13.48 and a 200 day simple moving average of $13.46. Enanta Pharmaceuticals, Inc. has a 52-week low of $7.05 and a 52-week high of $17.15. The firm has a market capitalization of $410.59 million, a PE ratio of -5.85 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. The company had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -2.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ENTA shares. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Enanta Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $19.50.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source